Rare immune cell holds key to predicting melanoma treatment success

A type of immune cell can help predict which patients may benefit most from cancer immunotherapies, researchers from King’s College London, Guy’s and St Thomas’ Hospital Trust, and the Francis Crick Institute have found.

Dyne Therapeutics sharpens case for two muscle disease therapies with updated data

Dyne Therapeutics shared promising clinical trial updates from two of its experimental RNA medicines for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy. The

May 21, 2024

Three months into bird flu outbreak in U.S. dairy cows, experts see deep-rooted problems in response

Three months since an outbreak of avian influenza in U.S. dairy cattle was declared, the country is failing to take the necessary steps to get

June 26, 2024

Gerresheimer remains on track in 1st half year 2024 – Biotech Investments

EQS-News: Gerresheimer AG / Key word(s): Half Year Results Gerresheimer remains on track in 1st half year 2024 11.07.2024 / 07:00 CET/CEST The issuer is

July 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.